 OptimizeRx has lost roughly 83 over the past twelve months despite showing impressive growth and profitability metrics. The market-wide sell-off is providing an opportunity to establish a position in OPRX. The company is expected to report double-digit growth over the next two years and hit around 95M in 2024, which is a 2.85x forward price-to-sales. 